SLC39A4 Antibody

What is SLC39A4 and why is it important in research?

SLC39A4, also known as ZIP4, is a critical zinc transporter that regulates cellular zinc uptake. This protein plays an essential role in maintaining zinc homeostasis, which is vital for numerous physiological processes. Dysregulation of SLC39A4 has been implicated in various pathological conditions, including cancer, neurodegenerative disorders, and metabolic diseases . Research on SLC39A4 is particularly significant because zinc is an essential micronutrient involved in cellular signaling, protein structure, and enzymatic reactions across multiple biological systems.

What applications are SLC39A4 antibodies typically used for?

SLC39A4 antibodies are validated for multiple research applications:

The selection of application should be based on experimental objectives, with optimization recommended for each specific antibody and experimental system .

How do I select the appropriate SLC39A4 antibody for my research?

When selecting an SLC39A4 antibody, consider:

• Target epitope: Different antibodies target distinct regions of SLC39A4. For example, some target amino acids 23-327, others target 281-380 or N-terminal regions . The epitope choice depends on your research question and accessibility of the epitope in your experimental conditions.

• Host species: Most SLC39A4 antibodies are raised in rabbits, though goat-derived antibodies are also available . Consider compatibility with other antibodies in multi-labeling experiments.

• Reactivity: Verify cross-reactivity with your species of interest. Many antibodies react with human and mouse SLC39A4, while some also detect rat SLC39A4 .

• Validation data: Review supplied validation data including Western blot bands (~60-80 kDa), IHC images, and flow cytometry profiles to ensure specificity .

• Clonality: Polyclonal antibodies offer broader epitope recognition but may have batch variability; monoclonal antibodies provide greater specificity and reproducibility .

What are common experimental controls when working with SLC39A4 antibodies?

Rigorous controls are essential when working with SLC39A4 antibodies:

• Positive controls: Use tissues or cell lines with known SLC39A4 expression. Validated positive controls include Hepa 1-6 hepatoma cells, D3 mouse embryonic stem cells, Colo320 cells, human jejunum tissue, and mouse small intestine .

• Negative controls: Include isotype controls (matched IgG from the same host species) to assess non-specific binding .

• Knockdown/knockout validation: SLC39A4 knockdown or knockout samples provide the most stringent controls for antibody specificity .

• Blocking peptide experiments: Pre-incubation of the antibody with immunizing peptide should abolish specific signals.

• Secondary antibody-only controls: To assess background from secondary antibody binding.

Each experimental system may require specific optimization of these control strategies.

How does SLC39A4 expression correlate with cancer progression and prognosis?

Multiple studies have revealed significant correlations between SLC39A4 expression and cancer outcomes:

These findings suggest SLC39A4 could serve as a prognostic biomarker and potential therapeutic target in multiple cancer types.

What methodological considerations are important when detecting SLC39A4 in different subcellular compartments?

SLC39A4 exhibits dynamic subcellular localization that is regulated by zinc availability, presenting specific technical challenges:

• Membrane vs. intracellular localization: Under low zinc conditions, SLC39A4 generally appears in the plasma membrane, while under high zinc conditions, it is often found internally associated with endosomes . This dynamic localization requires careful sample preparation and fixation protocols.

• Fixation methods:

  • For membrane-localized SLC39A4: Gentler fixation (2-4% paraformaldehyde) preserves membrane integrity

  • For intracellular SLC39A4: Permeabilization with 0.1-0.5% Triton X-100 is typically required

• Antibody accessibility considerations:

  • N-terminal targeting antibodies: More accessible when SLC39A4 is in the plasma membrane

  • C-terminal or internal region antibodies: May require more extensive permeabilization

• Proteolytic processing: SLC39A4 undergoes cell-specific proteolytic processing in response to low zinc concentrations, generating a soluble 35 kDa fragment and a 37 kDa transmembrane protein . This processing must be considered when interpreting Western blot results.

• Zinc manipulation experiments: Pre-treating cells with zinc chelators (like TPEN) or zinc supplementation can help validate SLC39A4 localization dynamics.

How can I optimize Western blot protocols for detecting SLC39A4?

Detecting SLC39A4 by Western blot requires specific optimization:

• Sample preparation:

  • Include protease inhibitors to prevent degradation

  • For membrane protein enrichment, consider using membrane fractionation protocols

  • Use appropriate lysis buffers containing 1% Triton X-100 or NP-40 for efficient extraction

• Protein loading and separation:

  • Load 20-50 μg of total protein

  • Use 8-10% SDS-PAGE gels for optimal separation

  • Expected molecular weight: 68-80 kDa, though may appear as multiple bands due to glycosylation and proteolytic processing

• Transfer conditions:

  • Transfer to PVDF membrane (preferred over nitrocellulose for this protein)

  • Consider using wet transfer systems for more efficient transfer of this membrane protein

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST

  • Primary antibody dilutions typically range from 1:1000-1:4000

  • Overnight incubation at 4°C often yields better results than shorter incubations

• Detection optimization:

  • Enhanced chemiluminescence (ECL) detection systems are generally sufficient

  • For low expression samples, consider signal enhancement systems or longer exposure times

What technical challenges should be anticipated when using SLC39A4 antibodies for immunohistochemistry?

Immunohistochemical detection of SLC39A4 presents specific challenges:

• Antigen retrieval: Optimization is critical, with studies indicating:

  • TE buffer pH 9.0 is often effective

  • Citrate buffer pH 6.0 provides an alternative approach

  • Heat-induced epitope retrieval (pressure cooker method) may be necessary for formalin-fixed tissues

• Signal specificity: SLC39A4 expression patterns vary by tissue type:

  • Strong expression in intestinal epithelial cells (useful positive control)

  • Expression in pancreatic beta-cells and choroid plexus epithelium

  • Cancer samples often show heterogeneous expression

• Background minimization:

  • Endogenous peroxidase blocking (3% H₂O₂, 10 minutes)

  • Protein blocking (5-10% normal serum matched to secondary antibody host)

  • Antibody dilution optimization (typically 1:50-1:500)

  • Additional washing steps may be necessary

• Detection systems:

  • For low abundance: Consider tyramide signal amplification

  • For co-localization studies: Fluorescent secondary antibodies with minimal cross-reactivity

• Control strategies:

  • Include known positive tissues (intestine, liver cancer)

  • Adjacent normal tissue can serve as internal control

  • Isotype control on serial sections

How does zinc availability affect SLC39A4 detection and experimental design?

Zinc concentrations significantly impact SLC39A4 biology and detection:

• Expression regulation: SLC39A4 expression is zinc-sensitive, with:

  • Upregulation under low zinc conditions

  • Downregulation under high zinc conditions

• Experimental considerations:

  • Cell culture media contains variable zinc levels

  • Serum supplementation introduces additional zinc variability

  • Consider using defined media with controlled zinc concentrations for reproducible results

• Zinc manipulation strategies:

  • Zinc depletion: Chelators (TPEN, DTPA) at 1-10 μM for 4-24 hours

  • Zinc supplementation: ZnCl₂ or ZnSO₄ at 10-100 μM for 4-24 hours

  • Time course experiments reveal dynamic regulation

• Detection implications:

  • Antibody accessibility may change with SLC39A4 localization

  • Proteolytic processing under low zinc alters detected band patterns

  • Sample processing time can impact zinc levels and SLC39A4 status

• Physiological context:

  • Dietary zinc status affects tissue SLC39A4 expression

  • Consider nutritional status when analyzing animal or human samples

What approaches can be used to study SLC39A4 function in relation to cancer progression?

Multiple experimental approaches can elucidate SLC39A4's role in cancer:

• Gene expression manipulation:

  • shRNA/siRNA knockdown: Lentivirus-mediated shRNA has successfully blocked EMT and metastasis in lung cancer models

  • Overexpression systems: Transfection of SLC39A4 expression constructs

  • CRISPR/Cas9 knockout: For complete protein elimination

• Functional assays:

  • Migration assays (wound healing, transwell)

  • Invasion assays (Matrigel-coated transwell)

  • EMT marker analysis (E-cadherin, vimentin, Snail, Twist)

  • Chemoresistance assays (particularly with cisplatin)

• Zinc transport assessment:

  • Fluorescent zinc indicators (FluoZin-3, Zinpyr-1)

  • ICP-MS quantification of intracellular zinc

  • Radioisotope (⁶⁵Zn) uptake assays

• Mechanistic investigations:

  • IL6/STAT3 pathway activation assessment

  • Protein interaction studies (co-immunoprecipitation)

  • Downstream target identification (RNA-seq, proteomics)

• In vivo models:

  • Xenograft models with SLC39A4-modulated cancer cells

  • Patient-derived xenografts with varying SLC39A4 expression

  • Metastasis models (tail vein injection, orthotopic implantation)

What are the most common issues when working with SLC39A4 antibodies and how can they be resolved?

Researchers frequently encounter specific challenges with SLC39A4 antibodies:

• Multiple bands in Western blot:

  • Cause: Post-translational modifications, proteolytic processing, or non-specific binding

  • Solution: Validate with positive controls, consider using reducing agents (DTT/BME), optimize primary antibody concentration, include protease inhibitors in sample preparation

• Weak or no signal in immunohistochemistry:

  • Cause: Epitope masking, inadequate antigen retrieval, or low expression

  • Solution: Optimize antigen retrieval conditions (try both pH 6.0 and pH 9.0 buffers), increase antibody concentration, extend incubation time, use signal amplification systems

• High background in immunofluorescence:

  • Cause: Non-specific binding, autofluorescence, or excessive antibody concentration

  • Solution: More extensive blocking (2-5% BSA + 5-10% normal serum), additional washing steps, lower antibody concentration, include 0.1-0.3% Triton X-100 in washing buffer

• Inconsistent results between experiments:

  • Cause: Variations in zinc levels, antibody lot variability, or sample handling differences

  • Solution: Standardize sample collection and processing, document antibody lot numbers, control environmental zinc exposure, include consistent positive controls

• Cross-reactivity with other ZIP family members:

  • Cause: Sequence homology between zinc transporters

  • Solution: Validate with knockout/knockdown samples, compare multiple antibodies targeting different epitopes, perform peptide competition assays

How can I quantify SLC39A4 expression levels accurately?

Accurate quantification of SLC39A4 requires appropriate methodologies:

• Western blot quantification:

  • Normalize to appropriate loading controls (β-actin, GAPDH, or Na⁺/K⁺ ATPase for membrane fractions)

  • Use digital imaging systems with linear dynamic range

  • Include standard curves with known protein amounts

  • Apply consistent exposure settings between experiments

• qRT-PCR approaches:

  • Design primers spanning exon-exon junctions

  • Validate primer efficiency (90-110%)

  • Normalize to multiple reference genes (GAPDH, β-actin, 18S rRNA)

  • Calculate using 2^(-ΔΔCt) method for relative quantification

• Flow cytometry quantification:

  • Use calibration beads with known antibody binding capacity

  • Calculate molecules of equivalent soluble fluorochrome (MESF)

  • Include consistent gating strategies

  • Report median fluorescence intensity (MFI) ratios to isotype controls

• Immunohistochemistry scoring:

  • Implement H-score method (0-300 scale combining intensity and percentage)

  • Use digital pathology software for unbiased assessment

  • Have multiple independent scorers for validation

  • Include reference standards in each batch

• ELISA-based methods:

  • Develop sandwich ELISA with validated antibody pairs

  • Include recombinant SLC39A4 protein standards

  • Optimize sample dilution to ensure measurements within linear range

  • Account for matrix effects with spike-and-recovery experiments

How can I effectively study the interaction between SLC39A4 and other proteins?

Investigating SLC39A4 protein interactions requires specialized approaches:

• Co-immunoprecipitation (Co-IP):

  • Use membrane-compatible lysis buffers (containing 0.5-1% NP-40 or digitonin)

  • Cross-linking may help stabilize transient interactions

  • Validate antibody suitability for IP applications

  • Consider native vs. denaturing conditions based on interaction type

• Proximity ligation assay (PLA):

  • Enables visualization of protein interactions in situ

  • Requires antibodies from different host species

  • Optimize fixation to preserve membrane structure

  • Include appropriate negative controls (single antibody)

• Bimolecular fluorescence complementation (BiFC):

  • Generate fusion constructs with split fluorescent protein fragments

  • Allows live-cell visualization of interactions

  • Consider N- vs. C-terminal tagging effects on protein function

  • Include protein localization controls

• FRET/FLIM analysis:

  • Label potential interaction partners with appropriate fluorophore pairs

  • Useful for dynamic interaction studies

  • Requires careful controls for spectral bleed-through

  • Can be combined with zinc sensors to study zinc-dependent interactions

• Mass spectrometry-based approaches:

  • Consider BioID or APEX proximity labeling for membrane proteins

  • Cross-linking mass spectrometry (XL-MS) can capture transient interactions

  • Label-free quantification to identify enriched interactors

  • Validate top candidates with orthogonal methods

How is SLC39A4 involved in resistance to chemotherapy?

Research indicates SLC39A4 plays significant roles in chemoresistance mechanisms:

• Cisplatin resistance:

  • SLC39A4 knockdown enhances cancer cell sensitivity to cisplatin-induced death

  • This effect appears linked to inhibition of stemness features in cancer cells

  • May involve modulation of DNA repair pathways

• EMT and stemness connection:

  • SLC39A4 promotes epithelial-mesenchymal transition

  • EMT is associated with increased chemoresistance

  • Cancer stem cell features are enhanced by SLC39A4 expression

• Zinc homeostasis effects:

  • Altered zinc levels affect activity of DNA repair enzymes

  • May influence apoptotic pathways

  • Could alter drug metabolism or efflux

• Signaling pathway modulation:

  • STAT3 pathway activation has been implicated in SLC39A4-mediated effects

  • MAPK signaling may be influenced by SLC39A4-regulated zinc levels

  • Potential crosstalk with drug resistance pathways

• Experimental approaches:

  • Combination therapy testing (SLC39A4 inhibition + chemotherapy)

  • Gene expression profiling before and after SLC39A4 modulation

  • Patient-derived xenograft models with varying SLC39A4 expression

What is the potential of SLC39A4 as a therapeutic target or biomarker?

Emerging research highlights SLC39A4's potential clinical applications:

• Prognostic biomarker potential:

  • Expression correlates with poor prognosis in multiple cancers

  • Could help stratify patients for aggressive therapy

  • May identify patients likely to develop chemoresistance

• Therapeutic targeting strategies:

  • Small molecule inhibitors of zinc transport function

  • Antibody-drug conjugates targeting cell-surface SLC39A4

  • siRNA/shRNA delivery systems for gene silencing

  • PROTAC approaches for protein degradation

• Combination therapy approaches:

  • Sensitization to conventional chemotherapy

  • Synergy with EMT inhibitors

  • Potential with immunotherapy (influence on tumor microenvironment)

• Biomarker implementation considerations:

  • IHC protocols for clinical laboratory implementation

  • Cut-off determination for "high" vs "low" expression

  • Correlation with other molecular markers

• Challenges and limitations:

  • Potential systemic effects of zinc transport inhibition

  • Compensatory mechanisms through other zinc transporters

  • Tissue-specific expression and function

How do post-translational modifications affect SLC39A4 function and detection?

Post-translational modifications significantly impact SLC39A4 biology:

• Glycosylation:

  • N-linked glycosylation affects protein stability and trafficking

  • Contributes to higher apparent molecular weight in Western blots (75-90 kDa vs. calculated 68 kDa)

  • May influence antibody accessibility to epitopes

  • PNGase F treatment can confirm glycosylation status

• Proteolytic processing:

  • Cell-specific cleavage in the N-terminal extracellular region

  • Generates ~35 kDa soluble fragment and ~37 kDa membrane fragment

  • Occurs in response to low zinc conditions

  • Affects band patterns observed in Western blots

• Phosphorylation:

  • May regulate subcellular localization and transport activity

  • Could influence protein-protein interactions

  • Phosphorylation-specific antibodies not widely available

• Ubiquitination:

  • Likely regulates protein turnover

  • May be zinc-responsive

  • Could affect protein extraction efficiency

• Detection considerations:

  • Sample preparation methods may preserve or disrupt modifications

  • Consider specific inhibitors during lysis (phosphatase inhibitors, deglycosylation inhibitors)

  • Multiple bands may represent modified forms rather than non-specific binding